Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cachexia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Cachexia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-003016-87 Sponsor Protocol Number: C3651003 Start Date*: 2023-03-13
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF G...
    Medical condition: Cachexia, a loss of weight due to the catabolism of muscle and fat tissue. The progressive worsening of cachexia impacts a cancer patient’s quality of life and contributes to poor survival.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) HU (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000461-12 Sponsor Protocol Number: CBYM338X2204 Start Date*: 2013-05-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double blind, placebo controlled, multi-centre study to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in chronic obstructive pulmonary disease patie...
    Medical condition: Cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) GOLD stage II to IV
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10006895 Cachexia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002968-10 Sponsor Protocol Number: 024 Start Date*: 2008-01-17
    Sponsor Name:Department of Medicine I, Clinical Dep. f. Oncology, University Hospital,
    Full Title: Treatment of Patients Suffering from Tumour Cachexia with Dronabinol (tetrahydrocannabinol) or Placebo Comparison of individually optimised dosages in a double blind, randomised parallel design
    Medical condition: tumour cachexia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000280-99 Sponsor Protocol Number: 201 Start Date*: 2004-10-04
    Sponsor Name:Ark Therapeutics, Ltd.
    Full Title: A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Dose-Titration Study of Imidapril Hydrochloride (EG006) in the Treatment of Cancer Cachexia
    Medical condition: Cancer Cachexia
    Disease: Version SOC Term Classification Code Term Level
    10006895 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008857-53 Sponsor Protocol Number: DC10004 Start Date*: 2009-02-25
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of Concomitant Megestrol + Formoterol in Patients with Cachexia and Advanced Malignancy
    Medical condition: Cancer-related cachexia, also known as Cancer Anorexia-Cachexia Syndrome (CACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019831-36 Sponsor Protocol Number: CACS-2010 Start Date*: 2011-04-21
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: A phase III randomized trial comparing two regimens for treatment of cancer anorexia / cachexia syndrome(CACS).
    Medical condition: Cancer anorexia / cachexia syndrome in patients with advanced tumors of different sites
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022486-10 Sponsor Protocol Number: MT-102-2001 Start Date*: 2010-11-02
    Sponsor Name:Myotec Therapeutics Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subject...
    Medical condition: Cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004340-67 Sponsor Protocol Number: EG006/208 Start Date*: 2009-04-21
    Sponsor Name:Ark Therapeutics Limited
    Full Title: A multi-centre, double-blind, randomised, placebo-controlled, phase IIa exploratory study of the effects of Imidapril on body weight and body composition in Non-Small Cell Lung Cancer patients with...
    Medical condition: Cancer Cachexia in Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000371-18 Sponsor Protocol Number: 220105 Start Date*: 2005-09-23
    Sponsor Name:Portsmouth Hospitals Trust
    Full Title: The use of Thalidomide as a treatment for the cachexia of incurable upper gastrointestinal adenocarcinomas:a randomised, double-blinded, placebo controlled trial.
    Medical condition: The cachexia associated with terminal gastrointestinal adenocarcinomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024342-30 Sponsor Protocol Number: CBYM338X2202 Start Date*: 2011-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the panc...
    Medical condition: Condition of cachexia in adults with stage IV metastatic non-small cell lung cancer or stage III/IV pancreatic adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003822-29 Sponsor Protocol Number: I1Q-MC-JDDG(b) Start Date*: 2012-03-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
    Medical condition: Muscle wasting and weakness associated with cancer of the pancreas that is locally advanced or metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2007-007725-46 Sponsor Protocol Number: ASBI 307 Start Date*: 2009-02-06
    Sponsor Name:Asubio Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 We...
    Medical condition: Cachexia associated with chronic obstructive pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-003271-61 Sponsor Protocol Number: BST204C02 Start Date*: 2018-01-15
    Sponsor Name:GREEN CROSS WellBeing
    Full Title: Phase IIa (therapeutic exploratory), multicenter, randomized, double-blind, placebocontrolled, 2-stage, 4-arm study exploring the effect of BST204 on cancer-related cachexia in patients with gastro...
    Medical condition: Patients with gastrointestinal (colon or gastric) cancer or NSCLC undergoing chemotherapy (treatment of cancer-related cachexia)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023649-31 Sponsor Protocol Number: HT-ANAM-302 Start Date*: 2011-07-29
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023648-34 Sponsor Protocol Number: HT-ANAM-301 Start Date*: 2011-09-15
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    14.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) DE (Completed) CZ (Completed) IT (Completed) SI (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002282-19 Sponsor Protocol Number: MENAC-2017-03 Start Date*: 2016-05-17
    Sponsor Name:Norwegian University of Science and technology
    Full Title: A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in a...
    Medical condition: cachexia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000570-22 Sponsor Protocol Number: 20060441 Start Date*: 2008-01-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer
    Medical condition: Muscle cachexia due to non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023650-36 Sponsor Protocol Number: HT-ANAM-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): An Extension Study (ROMANA-3)
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) NL (Completed) GB (Completed) ES (Completed) CZ (Completed) PL (Completed) DE (Completed) IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2017-000530-54 Sponsor Protocol Number: VS56151/17000277 Start Date*: 2018-01-16
    Sponsor Name:University of Copenhagen
    Full Title: The effect of cannibinols in patients with pancreatic cancer in the palliative state
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10037027 Protein-calorie malnutrition LLT
    20.0 100000004861 10064015 Cancer cachexia LLT
    20.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022897-14 Sponsor Protocol Number: PreMENAC-2011-01 Start Date*: 2011-05-02
    Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology
    Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II)
    Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 22:11:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA